U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07324642) titled 'A Phase 1 MAD Study of KINE-101 in Healthy Volunteers' on Dec. 09, 2025.
Brief Summary: This is a randomized, single-center, single-blind, placebo-controlled, dose-escalation Phase 1 clinical trial designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of multiple intravenous (IV) infusions of KINE-101 in healthy adult volunteers.
The study includes three sequential cohorts with a total of 24 subjects (8 subjects per cohort; 6 assigned to KINE-101 and 2 to placebo). Subjects in the treatment groups receive KINE-101 once daily for 7 consecutive days at doses corresponding to their assigned...